A review of self-report medication side effect questionnaires for mental health patients

Psychiatry Research

Volumn 219, Issue 3, 2014, Pages 664-673

  Ashoorian, Deena ^a   Davidson, Rowan ^b,c   Rock, Daniel ^b,c   Gudka, Sajni ^a   Clifford, Rhonda ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b North Metropolitan Health Service Mental Health   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adverse effect; Antipsychotic; Neuroleptic; Psychotropic; Subjective experience

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG SAFETY; HEALTH BELIEF; HUMAN; MENTAL PATIENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PEER REVIEW; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY CONTROL; QUESTIONNAIRE; SELF CONCEPT; SELF REPORT; SELF REPORT QUESTIONNAIRE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; FEMALE; MALE; MENTAL DISORDERS; MENTAL HEALTH; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; REPRODUCIBILITY;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH; MIDDLE AGED; PSYCHOMETRICS; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF REPORT;

EID: 84907598534     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.05.060     Document Type: Article

References (44)

1. Australian Institute of Health and Welfare (AIHW). Mental health services in Australia 2007-08. Mental Health Series, No.12, Cat. no. HSE 88. Canberra, 2010.
2. Ascher-Svanum H., Baojin Z., Faries D., Lacro J., Dolder C., Peng X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Preferences and Adherence 2008, 2:67-77.
3. Cabeza I.G., Amador M.S., Lopez C.A., Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophrenia Research 2000, 41:349-355.
4. Castle D., Morgan V., Jablensky A. Antipsychotic use in Australia: the patients' perspective. Australian & New Zealand Journal of Psychiatry 2002, 36:633-641.
5. Cerovecki A., Musil R., Klimke A., Seemuller F., Haen E., Schennach R., Kuhn K., Voz H., Riedel M. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013, 27:545-572.
6. Chapman S.C.E., Horne R. Medication nonadherence and psychiatry. Current Opinion in Psychiatry 2013, 26:446-452.
7. Crombie I. The Pocket Guide to Critical Appraisal: A Handbook for Healthcare Professionals 1996, BMJ Publishing Group, London.
8. Dassori A.M., Miller A.L., Weiden P.J. The approaches to schizophrenia communication (ASC) tool: including the patient perspective in treatment. Disease Management and Health Outcomes 2003, 11:699-708.
9. Day J.C., Wood G., Dewey M., Bentall R.P. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. The British Journal of Psychiatry 1995, 166:650-653.
10. Dott S.G., Weiden P., Hopwood P., Awad A.G., Hellewell J.S.E., Knesevich J., Kopala L., Miller A., Salzman C. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists. CNS Spectrums 2001, 6:333-338.
11. Edward K., Alderman C. Psychopharmacology Practice and Contexts 2013, Oxford University Press, Melbourne.
12. Fakhoury W.K.H., Wright D., Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline. International Clinical Psychopharmacology 2001, 16:153-162.
13. Farcas A.M., Farah C., Bojita M.T. Patients reporting of suspected adverse reactions to antidepressants. A pilot methodological study. Farmacia 2010, 58:255-263.
14. Foster J.M., Van der Molen T., Caeser M., Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiology and Drug Safety 2008, 17:278-296.
15. Gerlach J., Larsen E.B. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 1999, 99:113-117.
16. Goff D.C., Hill M., Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2010, 71:20-26.
17. Happell B., Manias E., Roper C. Wanting to be heard: mental health consumers' experiences of information about medication. International Journal of Mental Health Nursing 2004, 13:242-248.
18. Jordan S., Knight J., Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. International Nursing Review 2004, 51:208-221.
19. Junghan U.M., Leese M., Priebe S., Slade M. Staff and patient perspectives on unmet need and therapeutic alliance in community mental health services. The British Journal of Psychiatry 2007, 191:543-547.
20. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009, 62:e1-e34.
21. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J.S., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223.
22. Lindsley C.W. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ASC Chemical Neuroscience 2012, 3:630-631.
23. Lindstrom E., Lewander T., Malm U., Malt U., Lublin H., Ahlfors U.G. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordic Journal of Psychiatry 2001, 55:5-69.
24. Lingjaerde O., Ahlfors U., Bech P., Dencker S., Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987, 76:1-100.
25. Litwin M.S. How to Assess and Interpret Survey Psychometrics 2003, Sage Publications, London.
26. Llorca P.M. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Research 2008, 161:235-247.
27. Lohr K., Aaronson N., Alonso J., Burnam A., Patrick D.L., Perrin E., Stein R.E.K. Assessing health status and quality-of-life instruments: attributes and review criteria. Quality of Life Research 2002, 11:193-205.
28. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 2010, 67:26-36.
29. Mojtabai R., Corey-Lisle P.K., Ip E.H., Kopeykina I., Haeri S., Cohen L.J., Shumaker S. The patient assessment questionnaire: initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatry Research 2012, 200:857-866.
30. Morrison P., Gaskill D., Meehan T., Lunney P., Lawrence G., Collings P. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australian New Zealand Journal of Mental Health Nursing 2000, 9:166-176.
31. Murray C.J.L. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012, 380:2197-2223.
32. Naber D., Karow A. Good tolerability equals good results: the patient's perspective. European Neuropsychopharmacology 2001, 11(Supplement 4):S391-S396.
33. Naber D. Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiologia e psichiatria sociale 2008, 17:174-176.
34. Nosè M., Mazzi M.A., Esposito E., Bianchini M., Petrosemolo P., Ostuzzi G., Tansella M., Barbui C. Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective. Social Psychiatry & Psychiatric Epidemiology 2012, 47:157-164.
35. Olfson M., Mechanic D., Hansell S., Boyer C.A., Walkup J., Weiden P. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 2000, 51:216-222.
36. Slade M., Williams J., Bird V., Leamy M., Le Boutillier C. Recovery grows up. Journal of Mental Health 2012, 21:99-103.
37. Slade M. Everyday solutions for everyday problems: how mental health systems can support recovery. Psychiatric Services 2012, 63:702-704.
38. Staring A.B.P., Mulder C.L., Duivenvoorden H.J., De Haan L., Van der Gaag M. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophrenia Research 2009, 113:27-33.
39. Waddell L., Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. Journal of Psychopharmacology 2008, 22:238-243.
40. Weiden P.J., Miller A.L. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. Journal of Psychiatric Practice 2001, 7:41-47.
41. Wolters H.A., Knegtering R., Wiersma D., Van den Bosch R.J. The spectrum of subjective effects of antipsychotic medication. Acta Neuropsychiatrica 2003, 15:274-279.
42. Wolters H.A., Knegtering R., Wiersma D., Van den Bosch R.J. Evaluation of the subjects' response to antipsychotics questionnaire. International Clinical Psychopharmacology 2006, 21:63-69.
43. Wolters H.A., Knegtering H., Wiersma D., Van den Bosch R.J. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophrenia Research 2009, 112:114-118.
44. Yen C.F., Yu L., Tang T.C., Yen J.Y., Ko C.H., Chen C.C. Predictive value of self-stigma, insight, and perceived adverse effects of medication for the clinical outcomes in patients with depressive disorders. Journal of Nervous & Mental Disease 2009, 197:172-177.